Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRUGNASDAQ:MDWDNASDAQ:OKYONASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRUGBright Minds Biosciences$29.01-4.0%$32.34$0.93▼$79.02$204.35M-5.32824,901 shs26,810 shsMDWDMediWound$20.37+0.1%$17.46$12.78▼$24.00$220.16M0.391,241 shs44,100 shsOKYOOKYO Pharma$1.85+0.5%$1.36$0.81▼$1.98$62.60M-0.38131,392 shs2.46 million shsTVGNTevogen Bio$1.31+6.5%$1.08$0.26▼$3.09$240.90M-0.825.02 million shs1.36 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRUGBright Minds Biosciences-4.00%-12.09%-14.93%-19.39%+2,467.26%MDWDMediWound+0.15%-0.54%+13.36%+14.92%+15.67%OKYOOKYO Pharma+0.54%+25.00%+23.33%+65.92%+23.90%TVGNTevogen Bio+6.50%+15.93%+28.43%-7.42%+69.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRUGBright Minds Biosciences3.0008 of 5 stars3.64.00.00.03.52.50.0MDWDMediWound1.5521 of 5 stars3.51.00.00.01.80.80.6OKYOOKYO Pharma1.7097 of 5 stars3.53.00.00.00.91.70.0TVGNTevogen Bio2.9391 of 5 stars3.52.00.00.01.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRUGBright Minds Biosciences 3.25Buy$83.25186.97% UpsideMDWDMediWound 3.00Buy$31.2553.41% UpsideOKYOOKYO Pharma 3.00Buy$7.00278.38% UpsideTVGNTevogen Bio 3.00Buy$7.10441.98% UpsideCurrent Analyst Ratings BreakdownLatest OKYO, MDWD, DRUG, and TVGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.00 ➝ $31.005/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/12/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/7/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/2/2025MDWDMediWoundAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/29/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/21/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRUGBright Minds BiosciencesN/AN/AN/AN/A$5.86 per shareN/AMDWDMediWound$20.22M10.89N/AN/A$3.43 per share5.94OKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/ATVGNTevogen BioN/AN/AN/AN/A($1.10) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-5.85%-5.68%N/AMDWDMediWound-$6.72M-$3.07N/AN/AN/A-142.29%-82.17%-33.67%N/AOKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/AN/ATVGNTevogen Bio-$70KN/A0.00∞N/AN/A-396.07%749.97%N/ALatest OKYO, MDWD, DRUG, and TVGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MDWDMediWound-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A3/19/2025Q4 2024MDWDMediWound-$0.59-$0.36+$0.23-$0.36$5.79 million$5.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRUGBright Minds BiosciencesN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRUGBright Minds BiosciencesN/A126.0111.31MDWDMediWoundN/A2.111.99OKYOOKYO PharmaN/A0.28N/ATVGNTevogen BioN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRUGBright Minds Biosciences40.52%MDWDMediWound46.83%OKYOOKYO Pharma2.97%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipDRUGBright Minds Biosciences42.66%MDWDMediWound9.20%OKYOOKYO Pharma40.46%TVGNTevogen Bio73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableMDWDMediWound8010.81 million9.79 millionOptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionableTVGNTevogen Bio3183.89 million75.97 millionN/AOKYO, MDWD, DRUG, and TVGN HeadlinesRecent News About These CompaniesTevogen breidt doelgroep voor COVID-behandeling uit naar 65-plussersMay 23 at 11:06 PM | nl.investing.comTevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to FollowMay 23 at 3:49 PM | globenewswire.comTevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual Meeting on June 23, 2025May 22 at 2:08 PM | quiverquant.comTevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual MeetingMay 22 at 1:21 PM | globenewswire.comD. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)May 14, 2025 | marketbeat.comTevogen Bio's (TVGN) Buy Rating Reiterated at D. Boral CapitalMay 14, 2025 | americanbankingnews.comTevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical CompetitionMay 13, 2025 | nasdaq.comTevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient InnovationMay 12, 2025 | globenewswire.comTevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing FacilityMay 2, 2025 | nasdaq.comTevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder InterestMay 2, 2025 | globenewswire.comD. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)May 1, 2025 | marketbeat.comCD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | uk.finance.yahoo.comWhy Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Up 5.60%April 30, 2025 | aaii.comCD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million CommitmentApril 30, 2025 | globenewswire.comTevogen Bio shares surge on revenue forecastApril 29, 2025 | investing.comTevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage AccountsApril 29, 2025 | globenewswire.comTevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor FitzgeraldApril 29, 2025 | globenewswire.comTevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 BillionApril 28, 2025 | globenewswire.comTevogen Bio revises director resignation processApril 27, 2025 | uk.investing.comTevogen Bio past procedure aan voor aftreden bestuurdersApril 26, 2025 | nl.investing.comTevogen Bio Announces 2025 Annual MeetingApril 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Analysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueOKYO, MDWD, DRUG, and TVGN Company DescriptionsBright Minds Biosciences NASDAQ:DRUG$29.01 -1.21 (-4.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$28.86 -0.16 (-0.53%) As of 05/23/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.MediWound NASDAQ:MDWD$20.37 +0.03 (+0.15%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.34 -0.03 (-0.15%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.OKYO Pharma NASDAQ:OKYO$1.85 +0.01 (+0.54%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$1.80 -0.06 (-2.97%) As of 05/23/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Tevogen Bio NASDAQ:TVGN$1.31 +0.08 (+6.50%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.33 +0.02 (+1.53%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
